BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Aug 23, 2018
Translation in Brief

The self-destructing pancreas

A pair of independent papers from researchers from Washington University School of Medicine in St. Louis and Institut National de la Santé et de la Recherche Médicale (INSERM) illustrate how pancreatic β cells may contribute...
BioCentury | Nov 17, 2016
Translation in Brief

Hormones in harness

A compound that brings together the therapeutic benefits of glucagon (GCG) and triiodothyronine (T3) could treat multiple metabolic diseases without courting the off-target toxicities associated with the individual hormones. In a Cell study published last...
BioCentury | Jun 29, 2015
Product Development

Insights in interception

Four months after launching an R&D group to predict and prevent progression to disease, Janssen Research & Development LLC has revealed the center's first research collaboration in Type I diabetes, named two new disease areas...
BioCentury | Apr 3, 2014
Cover Story

Critical mass in diabetes

A University of Bremen group has found a new target-serine/threonine kinase 4-that can increase b cell mass and could represent an alternative to invasive islet cell transplants in patients with diabetes. 1 Next, the team...
BioCentury | Apr 15, 2010
Cover Story

ACE in the hole

American and Japanese researchers may have found a way to boost the efficacy of marketed angiotensin-converting enzyme inhibitors by combining them with inhibitors of chymase, 1 a protease that is abundant in cardiac tissue. The...
BioCentury | Dec 19, 2005
Strategy

Abgenix chronicles

...PFS) in metastatic colorectal cancer in patients who have failed chemotherapyK. 3/26/01 - Partners with Diabetogen...
BioCentury | Apr 11, 2005
Company News

TolerRx Inc., Diabetogen deal

...TolerRx acquired certain IP and material assets from Diabetogen related to anti-CD3 antibodies, including a patent...
...completed a Phase II trial to treat Type I diabetes. TolerRx Inc. , Cambridge, Mass. Diabetogen Biosciences Inc....
BioCentury | Apr 4, 2005
Finance

Ebb & Flow

...back to a state of quiescence." This week, TolerRx was to announce a deal with Diabetogen...
BioCentury | Mar 24, 2003
Company News

PanGeo board of directors update

...Gary Ullman, formerly president and CEO of Unitron Industries Ltd.; and Jim Youmans, director at Diabetogen Biosciences Inc....
Items per page:
1 - 10 of 17
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Aug 23, 2018
Translation in Brief

The self-destructing pancreas

A pair of independent papers from researchers from Washington University School of Medicine in St. Louis and Institut National de la Santé et de la Recherche Médicale (INSERM) illustrate how pancreatic β cells may contribute...
BioCentury | Nov 17, 2016
Translation in Brief

Hormones in harness

A compound that brings together the therapeutic benefits of glucagon (GCG) and triiodothyronine (T3) could treat multiple metabolic diseases without courting the off-target toxicities associated with the individual hormones. In a Cell study published last...
BioCentury | Jun 29, 2015
Product Development

Insights in interception

Four months after launching an R&D group to predict and prevent progression to disease, Janssen Research & Development LLC has revealed the center's first research collaboration in Type I diabetes, named two new disease areas...
BioCentury | Apr 3, 2014
Cover Story

Critical mass in diabetes

A University of Bremen group has found a new target-serine/threonine kinase 4-that can increase b cell mass and could represent an alternative to invasive islet cell transplants in patients with diabetes. 1 Next, the team...
BioCentury | Apr 15, 2010
Cover Story

ACE in the hole

American and Japanese researchers may have found a way to boost the efficacy of marketed angiotensin-converting enzyme inhibitors by combining them with inhibitors of chymase, 1 a protease that is abundant in cardiac tissue. The...
BioCentury | Dec 19, 2005
Strategy

Abgenix chronicles

...PFS) in metastatic colorectal cancer in patients who have failed chemotherapyK. 3/26/01 - Partners with Diabetogen...
BioCentury | Apr 11, 2005
Company News

TolerRx Inc., Diabetogen deal

...TolerRx acquired certain IP and material assets from Diabetogen related to anti-CD3 antibodies, including a patent...
...completed a Phase II trial to treat Type I diabetes. TolerRx Inc. , Cambridge, Mass. Diabetogen Biosciences Inc....
BioCentury | Apr 4, 2005
Finance

Ebb & Flow

...back to a state of quiescence." This week, TolerRx was to announce a deal with Diabetogen...
BioCentury | Mar 24, 2003
Company News

PanGeo board of directors update

...Gary Ullman, formerly president and CEO of Unitron Industries Ltd.; and Jim Youmans, director at Diabetogen Biosciences Inc....
Items per page:
1 - 10 of 17